1.alpha.,24-(OH).sub.2 -cholecalciferol emulsion composition and method
for treating psoriasis
    1.
    发明授权
    1.alpha.,24-(OH).sub.2 -cholecalciferol emulsion composition and method for treating psoriasis 失效
    1α,24-(OH)2 - 胆钙化醇乳剂组合物和治疗牛皮癣的方法

    公开(公告)号:US5612327A

    公开(公告)日:1997-03-18

    申请号:US428106

    申请日:1995-04-28

    摘要: A 1.alpha.,24-(OH).sub.2 --V.D.sub.3 cream composition comprising(a) a therapeutically effective amount of 1.alpha.,24-(OH).sub.2 --V.D.sub.3,(b) an oil phase component including(i) a solid oil component composed of 5 to 20 parts by weight of white petrolatum and 5 to 15 parts by weight of higher alcohols and(ii) a liquid oil component comprising of 3 to 10 parts by weight of squalane,(c) an aqueous phase component, and(d) 2.5 to 7.5 parts by weight at least two surfactants, wherein the 1.alpha.,24-(OH).sub.2 --V.D.sub.3 cream composition has a weight ratio of the solid oil component to the liquid oil component (i.e., solid oil component/liquid oil component) of at least approximately 2, the higher alcohols are composed of stearyl alcohol and cetyl alcohol, the weight ratio of the stearyl alcohol to the higher alcohols (i.e., stearyl alcohol/higher alcohols) is approximately 0.65 to approximately 0.9, at least 50% by weight of the surfactants is at least one surfactant having an HLB value of approximately 5 or less, and the HLB value of the surfactants as a whole is approximately 8 to approximately 18.

    摘要翻译: PCT No.PCT / JP94 / 01443 Sec。 371日期:1995年4月28日 102(e)日期1995年4月28日PCT 1994年9月1日PCT公布。 公开号WO95 / 06482 日期:1995年3月9日A 1α,24-(OH)2-V.D3乳膏组合物,其包含(a)治疗有效量的1α,24-(OH)2-V.D3,(b)油相 组分包括(i)由5至20重量份的白凡士林和5至15重量份的高级醇组成的固体油组分和(ii)包含3至10重量份的角鲨烷的液体油组分( c)水相组分,和(d)2.5至7.5重量份的至少两种表面活性剂,其中所述1α,24-(OH)2-V.D3乳膏组合物具有固体油组分与 液体油组分(即固体油组分/液体油组分)至少约为2,高级醇由硬脂醇和鲸蜡醇组成,硬脂醇与高级醇的重量比(即硬脂醇/更高 醇)为约0.65至约0.9,至少50重量%的表面活性剂是至少一种HLB值为约 实际为5以下,表面活性剂整体的HLB值约为8〜18。

    Sustained release preparation
    2.
    发明授权
    Sustained release preparation 失效
    持续释放准备

    公开(公告)号:US4814176A

    公开(公告)日:1989-03-21

    申请号:US817649

    申请日:1986-01-10

    摘要: A sustained release preparation comprising:(a) chitin, chitosan, or a mixture thereof(b) anionic polymer compounds such as those having a carboxyl group, a sulfonic acid group, or a group capable of providing the same, and(c) pharmaceutically active agents.This sustained release preparation can provide the desired sustained-release or dissolution of the pharmaceutically active agents in human organs irrespective of the acidity (i.e., pH conditions) therein.

    摘要翻译: 一种持续释放制剂,其包含:(甲),壳聚糖或其混合物(b)阴离子聚合物化合物,例如具有羧基,磺酸基或能够提供相同基团的基团的阴离子聚合物化合物,和(c) 活性剂。 这种持续释放制剂可以提供药物活性剂在人体器官中的期望的缓释或溶解,而与其中的酸度(即pH条件)无关。

    External pharmaceutical composition and methods of use
    3.
    发明授权
    External pharmaceutical composition and methods of use 失效
    外用药物组成及使用方法

    公开(公告)号:US4789667A

    公开(公告)日:1988-12-06

    申请号:US771764

    申请日:1985-09-03

    摘要: A pharmaceutical composition for external use with the enhanced penetration of a pharmacologically active agent through the skin or mucosa of a warm-blooded animal, said composition comprising(A) a pharmaceutically effective amount of the pharmacologically active agent, and(B) an optically active or inactive pyroglutamate of the following formula ##STR1## wherein R represents a linear, branched or cyclic alkyl or alkenyl group having 10 to 14 carbon atoms,as a penentration enhancer.

    摘要翻译: 一种外用的药物组合物,其具有通过温血动物的皮肤或粘膜增强的药理活性剂渗透性,所述组合物包含(A)药学有效量的药理活性剂,和(B)光学活性剂 或不活泼的焦谷氨酸盐,其中R表示具有10至14个碳原子的直链,支链或环状烷基或烯基作为缩合增强剂。

    Sustained release preparation
    5.
    发明授权
    Sustained release preparation 失效
    持续释放准备

    公开(公告)号:US4755544A

    公开(公告)日:1988-07-05

    申请号:US870480

    申请日:1986-06-04

    摘要: A sustained release preparation comprising:(a) a non-anionic cellulose ether(b) a methoxyethylene-maleic anhydride copolymer or the hydrolyzate thereof, and(c) pharmaceutically active agents.This sustained release preparation can provide the desired sustained-release or dissolution of the pharmaceutically active agents in human organs irrespective of the acidity (i.e., pH conditions) therein.

    摘要翻译: 一种缓释制剂,其包含:(a)非阴离子纤维素醚(b)甲氧基亚乙基 - 马来酸酐共聚物或其水解产物,和(c)药用活性剂。 这种持续释放制剂可以提供药物活性剂在人体器官中的期望的缓释或溶解,而与其中的酸度(即pH条件)无关。